JP2003504397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003504397A5 JP2003504397A5 JP2001510445A JP2001510445A JP2003504397A5 JP 2003504397 A5 JP2003504397 A5 JP 2003504397A5 JP 2001510445 A JP2001510445 A JP 2001510445A JP 2001510445 A JP2001510445 A JP 2001510445A JP 2003504397 A5 JP2003504397 A5 JP 2003504397A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- alkyl
- hydroxy
- prostaglandin
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 description 29
- 125000000217 alkyl group Chemical group 0.000 description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 16
- 125000003545 alkoxy group Chemical group 0.000 description 14
- 229910052736 halogen Inorganic materials 0.000 description 13
- 150000002367 halogens Chemical class 0.000 description 13
- 230000002997 prostaglandinlike Effects 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 125000004043 oxo group Chemical group O=* 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 8
- 125000000623 heterocyclic group Chemical group 0.000 description 8
- 150000002431 hydrogen Chemical class 0.000 description 7
- 125000001931 aliphatic group Chemical group 0.000 description 6
- 125000004104 aryloxy group Chemical group 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 3
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 2
- 0 CC(CC(CC*IN)NN)(NI)IC(**)C(BC(*)=*)* Chemical compound CC(CC(CC*IN)NN)(NI)IC(**)C(BC(*)=*)* 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- FGOJCPKOOGIRPA-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 5-oxoazepane-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CCC1=O FGOJCPKOOGIRPA-UHFFFAOYSA-N 0.000 description 1
- CDUVSQMTLOYKTR-ZHALLVOQSA-N 13,14-dihydro-15-oxoprostaglandin E1 Chemical compound CCCCCC(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O CDUVSQMTLOYKTR-ZHALLVOQSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010028740 Nasal dryness Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 1
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14362799P | 1999-07-14 | 1999-07-14 | |
| US60/143,627 | 1999-07-14 | ||
| PCT/JP2000/004696 WO2001005388A2 (en) | 1999-07-14 | 2000-07-13 | Use of a fatty derivative for the treatment of external secretiondisorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008164252A Division JP5052423B2 (ja) | 1999-07-14 | 2008-06-24 | 外分泌障害処置剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003504397A JP2003504397A (ja) | 2003-02-04 |
| JP2003504397A5 true JP2003504397A5 (enExample) | 2006-02-23 |
| JP4167828B2 JP4167828B2 (ja) | 2008-10-22 |
Family
ID=22504885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001510445A Expired - Fee Related JP4167828B2 (ja) | 1999-07-14 | 2000-07-13 | 外分泌障害処置剤 |
| JP2008164252A Expired - Fee Related JP5052423B2 (ja) | 1999-07-14 | 2008-06-24 | 外分泌障害処置剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008164252A Expired - Fee Related JP5052423B2 (ja) | 1999-07-14 | 2008-06-24 | 外分泌障害処置剤 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US6566398B1 (enExample) |
| EP (1) | EP1223925B1 (enExample) |
| JP (2) | JP4167828B2 (enExample) |
| KR (1) | KR100750553B1 (enExample) |
| CN (4) | CN101829120B (enExample) |
| AR (2) | AR029381A1 (enExample) |
| AT (1) | ATE344027T1 (enExample) |
| AU (1) | AU779936B2 (enExample) |
| BR (1) | BRPI0012387B1 (enExample) |
| CA (1) | CA2377661C (enExample) |
| CZ (1) | CZ303958B6 (enExample) |
| DE (1) | DE60031710T2 (enExample) |
| DK (1) | DK1223925T3 (enExample) |
| ES (1) | ES2273706T3 (enExample) |
| HK (1) | HK1048443B (enExample) |
| HU (1) | HU229318B1 (enExample) |
| IL (2) | IL147440A0 (enExample) |
| MX (1) | MXPA02000437A (enExample) |
| NO (1) | NO323908B1 (enExample) |
| PT (1) | PT1223925E (enExample) |
| RU (1) | RU2264816C2 (enExample) |
| TR (1) | TR200200065T2 (enExample) |
| TW (1) | TWI225398B (enExample) |
| WO (1) | WO2001005388A2 (enExample) |
| ZA (1) | ZA200109726B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7732487B2 (en) * | 2001-11-19 | 2010-06-08 | Sucampo Ag | Method for treating a disease or condition responsive to opening of C1C-2 channel |
| AU2003235452A1 (en) * | 2002-06-14 | 2003-12-31 | Alcon, Inc. | Use of hydroxyeicosatetraenoic acid compounds to treat dry mouth |
| US20040076695A1 (en) * | 2002-07-08 | 2004-04-22 | Advanced Vision Research | EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia |
| US20040185075A1 (en) | 2003-01-31 | 2004-09-23 | Maria Dalko | Use of at least one (dihydro)jasmonic acid derivative for treating dry skin |
| FR2850571B1 (fr) * | 2003-01-31 | 2006-07-07 | Oreal | Utilisation d'un derive d'acide(dihydro) jasmonique pour le traitement des peaux seches |
| US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| US9216106B2 (en) * | 2003-04-09 | 2015-12-22 | Directcontact Llc | Device and method for the delivery of drugs for the treatment of posterior segment disease |
| US20050208102A1 (en) * | 2003-04-09 | 2005-09-22 | Schultz Clyde L | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| US20050074497A1 (en) * | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| US8541468B2 (en) | 2003-10-06 | 2013-09-24 | Ophtecs Corporation | Ophthalmic composition for treating tear dysfunction |
| US7923471B2 (en) | 2004-05-14 | 2011-04-12 | Alcon, Inc. | Method of treating dry eye disorders and uveitis |
| KR20070040381A (ko) * | 2004-07-01 | 2007-04-16 | 셰펜스 아이 리써치 | 눈의 장애 및 상태를 치료하는 조성물 및 방법 |
| US20070265341A1 (en) * | 2004-07-01 | 2007-11-15 | The Schepens Eye Research Institute Inc. | Compositions and methods for treating eye disorders and conditions |
| US8202909B2 (en) * | 2005-01-27 | 2012-06-19 | Sucampo Ag | Method for treating central nervous system disorders |
| CN103919783A (zh) * | 2005-03-04 | 2014-07-16 | 苏坎波公司 | 治疗外周血管病的方法和组合物 |
| US7638142B2 (en) * | 2005-10-12 | 2009-12-29 | Vitamin Science, Inc. | Therapeutic composition for the treatment of dry eye syndrome |
| NZ570190A (en) | 2006-01-24 | 2011-03-31 | Sucampo Ag | Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound |
| WO2008108322A2 (en) * | 2007-02-27 | 2008-09-12 | Sucampo Ag | Composition and method for protecting mitochondria |
| US20090053309A1 (en) * | 2007-08-24 | 2009-02-26 | Axiomedic Ltd., Gibraltar | Adhesive compositions for the treatment of xerostomia |
| US9161909B2 (en) | 2007-08-24 | 2015-10-20 | Axiomedic Ltd. | Adhesive compositions for the treatment of xerostomia |
| US20090082442A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched lubiprostone |
| US9597278B2 (en) | 2008-11-13 | 2017-03-21 | David A. Hamlin | Compositions and methods for alleviating hyposalivation and for providing oral comfort |
| US9884082B2 (en) | 2008-11-13 | 2018-02-06 | David A. Hamlin | Compositions and methods for alleviating hyposalivation and for providing oral comfort |
| EP2389939A1 (en) * | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
| JP2013542838A (ja) | 2010-11-16 | 2013-11-28 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ドライアイを治療するためのシステムおよび方法 |
| US9821159B2 (en) | 2010-11-16 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Stimulation devices and methods |
| US10709680B2 (en) | 2011-07-18 | 2020-07-14 | Physicians Recommended Nutriceuticals, Llc | Methods for treating dry eye |
| US9115078B2 (en) | 2011-07-18 | 2015-08-25 | Physicians Recommended Nutriceuticals, Llc | Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands |
| US20210121430A1 (en) | 2011-07-18 | 2021-04-29 | Prn Physician Recommended Nutriceuticals, Llc | Omega-3 fatty acid supplementation for use in treating dry eye |
| US9381183B2 (en) | 2012-07-18 | 2016-07-05 | Physicians Recommended Nutriceuticals, Llc | Methods for improving the quality of the meibum composition of meibomian glands |
| SG10201606442QA (en) * | 2011-08-05 | 2016-09-29 | Sucampo Ag | Method for treating schizophrenia |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| AU2014253754C1 (en) | 2013-04-19 | 2015-07-30 | Oculeve, Inc. | Nasal stimulation devices and methods |
| MX2017005204A (es) * | 2014-10-22 | 2017-12-14 | Oculeve Inc | Dispositivos y métodos de estimulación para tratar el ojo seco. |
| EP3452166A4 (en) | 2016-05-02 | 2019-12-18 | Oculeve, Inc. | INTRANASAL STIMULATION FOR THE TREATMENT OF DISEASES OF MEIBOM'S GLANDS AND BLEPHARITIS |
| KR20210003716A (ko) | 2018-04-26 | 2021-01-12 | 라이온 가부시키가이샤 | 외분비 촉진제 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4131651A (en) * | 1977-10-25 | 1978-12-26 | Barnes-Hind Pharmaceuticals, Inc. | Treatment of dry eye |
| US4409205A (en) * | 1979-03-05 | 1983-10-11 | Cooper Laboratories, Inc. | Ophthalmic solution |
| IE49783B1 (en) | 1979-05-18 | 1985-12-11 | Efamol Ltd | Pharmaceutical and dietary composition comprising epsilon-linolenic acids |
| GB8319073D0 (en) | 1983-07-14 | 1983-08-17 | Efamol Ltd | Fatty acid compositions |
| JPH07103096B2 (ja) * | 1987-01-28 | 1995-11-08 | 株式会社上野製薬応用研究所 | プロスタグランジンｄ類およびそれを含む鎮静・睡眠剤 |
| JPH0688966B2 (ja) * | 1987-01-28 | 1994-11-09 | 株式会社アールテック・ウエノ | プロスタグランジンｅ類およびそれを含む抗潰瘍剤 |
| DE3711164A1 (de) | 1987-04-02 | 1988-10-20 | Zeiss Carl Fa | Steckelementeinrichtung zur halterung von bauteilen in stapeln |
| CA1324129C (en) * | 1987-04-30 | 1993-11-09 | Ryuzo Ueno | Prostaglandins of the f series |
| JPS63277604A (ja) * | 1987-05-11 | 1988-11-15 | Showa Denko Kk | α−リノレン酸含有化粧料 |
| JPH0692305B2 (ja) * | 1987-05-15 | 1994-11-16 | 株式会社上野製薬応用研究所 | 体温上昇剤 |
| ATE108330T1 (de) * | 1987-09-18 | 1994-07-15 | R Tech Ueno Ltd | Hypotensive okulare mittel. |
| SU1673123A1 (ru) * | 1987-12-04 | 1991-08-30 | Научно-исследовательский институт морфологии человека АМН СССР | Способ лечени болезни и синдрома Шегрена |
| JP2579193B2 (ja) | 1988-07-19 | 1997-02-05 | 小野薬品工業株式会社 | １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体 |
| WO1990001323A1 (en) | 1988-08-12 | 1990-02-22 | Bernstein Joel E | Method and composition for treating and preventing dry skin disorders |
| CA2027814C (en) * | 1989-10-20 | 1996-07-30 | Ryuji Ueno | Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds |
| CA2039420C (en) * | 1990-04-04 | 1996-12-10 | Ryuji Ueno | Treatment of cataract with 15-keto-prostaglandin compounds |
| JPH07100655B2 (ja) * | 1990-04-04 | 1995-11-01 | 株式会社アールテック・ウエノ | 白内障処置剤 |
| EP0455448B1 (en) * | 1990-05-01 | 1998-12-09 | R-Tech Ueno Ltd. | Treatment of pancreatic disease with 15-keto-prostaglandin E compounds |
| JPH07113012B2 (ja) * | 1991-01-29 | 1995-12-06 | 株式会社アールテック・ウエノ | 新規１５−ケト−プロスタグランジン類 |
| ATE141794T1 (de) * | 1991-03-14 | 1996-09-15 | R Tech Ueno Ltd | Stimulierung von wundheilung mit 15-keto- prostaglandinverbindungen |
| US5369127A (en) * | 1993-04-21 | 1994-11-29 | Allergan, Inc. | 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents |
| JP3183615B2 (ja) * | 1994-06-03 | 2001-07-09 | 株式会社アールテック・ウエノ | 肝・胆道系疾患処置剤 |
| CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
| TW420611B (en) * | 1995-03-10 | 2001-02-01 | R Tech Ueno Ltd | Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder |
| US5696166A (en) | 1995-10-31 | 1997-12-09 | Yanni; John M. | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
| US6211197B1 (en) * | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| WO2000038663A2 (en) | 1998-12-24 | 2000-07-06 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
| AU2183800A (en) * | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Prostaglandin e agonists for treatment of dry eye |
| US8202909B2 (en) * | 2005-01-27 | 2012-06-19 | Sucampo Ag | Method for treating central nervous system disorders |
| CN103919783A (zh) * | 2005-03-04 | 2014-07-16 | 苏坎波公司 | 治疗外周血管病的方法和组合物 |
-
2000
- 2000-07-12 TW TW089113876A patent/TWI225398B/zh not_active IP Right Cessation
- 2000-07-13 MX MXPA02000437A patent/MXPA02000437A/es active IP Right Grant
- 2000-07-13 US US09/615,703 patent/US6566398B1/en not_active Expired - Lifetime
- 2000-07-13 TR TR2002/00065T patent/TR200200065T2/xx unknown
- 2000-07-13 CN CN2010101574518A patent/CN101829120B/zh not_active Expired - Fee Related
- 2000-07-13 CZ CZ20020133A patent/CZ303958B6/cs not_active IP Right Cessation
- 2000-07-13 EP EP00944426A patent/EP1223925B1/en not_active Expired - Lifetime
- 2000-07-13 ES ES00944426T patent/ES2273706T3/es not_active Expired - Lifetime
- 2000-07-13 KR KR1020027000471A patent/KR100750553B1/ko not_active Expired - Fee Related
- 2000-07-13 HU HU0202400A patent/HU229318B1/hu not_active IP Right Cessation
- 2000-07-13 JP JP2001510445A patent/JP4167828B2/ja not_active Expired - Fee Related
- 2000-07-13 AU AU58533/00A patent/AU779936B2/en not_active Ceased
- 2000-07-13 CN CNB2006101215152A patent/CN100548977C/zh not_active Expired - Fee Related
- 2000-07-13 CA CA2377661A patent/CA2377661C/en not_active Expired - Lifetime
- 2000-07-13 CN CN00810238A patent/CN1399548A/zh active Pending
- 2000-07-13 DE DE60031710T patent/DE60031710T2/de not_active Expired - Lifetime
- 2000-07-13 HK HK03100518.0A patent/HK1048443B/en not_active IP Right Cessation
- 2000-07-13 RU RU2002103597/15A patent/RU2264816C2/ru not_active IP Right Cessation
- 2000-07-13 CN CN200910205219A patent/CN101695495A/zh active Pending
- 2000-07-13 IL IL14744000A patent/IL147440A0/xx unknown
- 2000-07-13 PT PT00944426T patent/PT1223925E/pt unknown
- 2000-07-13 DK DK00944426T patent/DK1223925T3/da active
- 2000-07-13 AT AT00944426T patent/ATE344027T1/de active
- 2000-07-13 BR BRPI0012387A patent/BRPI0012387B1/pt not_active IP Right Cessation
- 2000-07-13 WO PCT/JP2000/004696 patent/WO2001005388A2/en not_active Ceased
- 2000-07-14 AR ARP000103635A patent/AR029381A1/es not_active Application Discontinuation
-
2001
- 2001-11-27 ZA ZA200109726A patent/ZA200109726B/en unknown
-
2002
- 2002-01-02 IL IL147440A patent/IL147440A/en active IP Right Grant
- 2002-01-11 NO NO20020133A patent/NO323908B1/no not_active IP Right Cessation
-
2003
- 2003-03-04 US US10/377,743 patent/US20030171438A1/en not_active Abandoned
-
2004
- 2004-11-23 US US10/994,364 patent/US7396946B2/en not_active Expired - Fee Related
-
2008
- 2008-06-24 JP JP2008164252A patent/JP5052423B2/ja not_active Expired - Fee Related
-
2009
- 2009-12-03 AR ARP090104665A patent/AR074465A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003504397A5 (enExample) | ||
| RU2002103597A (ru) | Композиция для лечения нарушений внешней секреции | |
| AU779936B2 (en) | Composition for treatment of external secretion disorders | |
| JP2010031041A (ja) | 降圧脂質（プロスタグランジン誘導体）およびチモロールの組成物ならびにその使用方法 | |
| WO2000004898A1 (en) | Ophthalmic compositions for treating ocular hypertension | |
| JP3139766B2 (ja) | Ｐｇｆ１―アルコールおよび眼圧低下剤としてのこれらの使用 | |
| JP2002521333A (ja) | 高眼圧治療用眼薬組成物 | |
| JP2006513232A5 (enExample) | ||
| JP2003527430A5 (enExample) | ||
| AU2001239551B2 (en) | Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof | |
| JP2006506381A5 (enExample) | ||
| JP5222462B2 (ja) | 眼科用組成物 | |
| JPH0770054A (ja) | 生化学的拮抗および疾患処置剤 | |
| JP5224625B2 (ja) | 眼科手術において眼圧を制御するための組成物 | |
| JP5579658B2 (ja) | ピペリジニルプロスタグランジンｅ類似体 | |
| JP2003526660A5 (enExample) | ||
| KR20080104024A (ko) | 만성 폐쇄성 폐질환의 치료를 위한 방법 및 조성물 | |
| JP2004538306A5 (enExample) | ||
| KR20080012407A (ko) | 고안압증 및 녹내장 치료용 조성물 | |
| JPH07103030B2 (ja) | 生化学的拮抗及び疾患処置剤 | |
| WO2003018025A1 (en) | Method and composition for treatment of ocular hypertension and glaucoma | |
| AU2001241143A1 (en) | Composition for use in treatment of ocular hypertension and glaucoma | |
| JP2006526637A (ja) | 医薬としての８−アザプロスタグランジンカーボネートおよびチオカーボネート類似体 | |
| JP2005519978A5 (enExample) | ||
| KR20020081438A (ko) | 고안압증 및 녹내장 치료용 조성물 |